Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
38.63
-0.27 (-0.69%)
Dec 20, 2024, 4:00 PM EST - Market closed
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for XENE stock have an average target of 56.67, with a low estimate of 49 and a high estimate of 65. The average target predicts an increase of 46.70% from the current stock price of 38.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for XENE stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 5 | 5 | 4 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +37.20% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +37.20% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +55.32% | Nov 13, 2024 |
| Raymond James | Raymond James | Buy Initiates $50 | Buy | Initiates | $50 | +29.43% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $53 | Strong Buy | Initiates | $53 | +37.20% | Oct 1, 2024 |
Financial Forecast
Revenue This Year
300.00K
Revenue Next Year
5.10M
from 300.00K
Increased by 1,599.99%
EPS This Year
-3.15
from -2.73
EPS Next Year
-3.67
from -3.15
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.3M | 78.8M | 113.5M | |||
| Avg | 300,002 | 5.1M | 43.3M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 26,149.8% | 2,126.1% | |||
| Avg | - | 1,600.0% | 749.4% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.90 | -2.53 | -2.95 | |||
| Avg | -3.15 | -3.67 | -3.97 | |||
| Low | -3.48 | -4.18 | -4.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.